Chemical Namepegcetacoplan
Dosage FormInjection (subcutaneous; 1,080 mg/20 mL (54 mg/mL))
Drug ClassComplement inhibitors
CompanyApellis Pharmaceuticals
Approval Year2021


  • For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Document TitleYearSource
Empaveli (pegcetacoplan) Prescribing Information.2021Apellis Pharmaceuticals, Inc., Waltham, MA
Document TitleYearSource
Australian public assessment report for pegceacoplan. 2022Australian Government: Department of Health
Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: a systematic review on efficacy and safety.2022Research and Practice in Thrombosis and Haemostasis
Drug updated on 5/30/2023

More on this drug: Clinical Trials